Clinical Trials Logo

Pancreas clinical trials

View clinical trials related to Pancreas.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04764396 Terminated - Pancreas Clinical Trials

Assessing Effects of Heparin Priming and Pass Number on Tissue Quality of Fine Needle Biopsies

Start date: March 12, 2021
Phase: N/A
Study type: Interventional

This is a randomized study that will enroll patients scheduled for an endoscopic ultrasound biopsy of a pancreas lesion to be in the heparin or saline group during the procedure. The purpose of this study is to examine the effect of blood contamination, heparin priming of the fine needle biopsies, and pass number on tumor tissue quality in fine needle biopsies. The hypothesis for this study is that fine needle biopsy tissue quality of pancreatic masses decreases with increasing pass number due to blood contamination; this blood contamination can be ameliorated with priming of the needle with an anticoagulant such as heparin.

NCT ID: NCT02244164 Terminated - Type 2 Diabetes Clinical Trials

Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.

Start date: October 2014
Phase: N/A
Study type: Interventional

Incretinomimetics and inhibitors of dipeptidyl peptidase-4 (DPP-4) are new treatments for diabetes. Previous retrospective studies have shown that these treatments induced an increase in pancreatic mass with potentially a risk for pancreatitis and development of precancerous lesions. The aim of our study is to provide a better understanding of the pathophysiological mechanisms of increased volume and / or pancreatic exocrine secretion when exposed to certain treatment of type 2 diabetes.

NCT ID: NCT00557596 Terminated - Carcinoma Clinical Trials

A Phase 1-2, XIAP Antisense AEG35156 With Gemcitabine in Patients With Advanced Pancreatic Cancer

Start date: September 2007
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label multicenter, phase 1-2 study. Following determination of the recommended AEG35156 dose in combination with gemcitabine in the initial Phase 1 part of this study, additional patients will be enrolled in the Phase 2 part of the study to assess the activity of the combination first-line in advanced pancreatic cancer.